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Randomized Trial of Percutaneous Coronary Intervention
for Subacute Infarct-Related Coronary Artery Occlusion
to Achieve Long-Term Patency and Improve
Ventricular Function
The Total Occlusion Study of Canada (TOSCA)–2 Trial
Vladimír Dzˇavík, MD; Christopher E. Buller, MD; Gervasio A. Lamas, MD; James M. Rankin, MD;
G.B. John Mancini, MD; Warren J. Cantor, MD; Ronald J. Carere, MD; John R. Ross, MD;
Deborah Atchison, PhD; Sandra Forman, MA; Boban Thomas, MD; Pawel Buszman, MD;
Carlos Vozzi, MD; Anthony Glanz, MD; Eric A. Cohen, MD; Peter Meiar, MD; Gerald Devlin, MD;
Alice Mascette, MD; George Sopko, MD; Genell L. Knatterud, PhD; Judith S. Hochman, MD;
for the TOSCA-2 Investigators
Background—In the present study, we sought to determine whether opening a persistently occluded infarct-related artery
(IRA) by percutaneous coronary intervention (PCI) in patients beyond the acute phase of myocardial infarction (MI)
improves patency and indices of left ventricular (LV) size and function.
Methods and Results—Between May 2000 and July 2005, 381 patients with an occluded native IRA 3 to 28 days after MI
(median 10 days) were randomized to PCI with stenting (PCI) or optimal medical therapy alone. Repeat coronary and
LV angiography was performed 1 year after randomization (n332, 87%). Coprimary end points were IRA patency and
change in LV ejection fraction. Secondary end points included change in LV end-systolic and end-diastolic volume
indices and wall motion. PCI was successful in 92%. At 1 year, 83% of PCI versus 25% of medical therapy–only
patients had a patent IRA (P0.001). LV ejection fraction increased significantly (P0.001) in both groups, with no
between-group difference: PCI 4.28.9 (n150) versus medical therapy 3.58.2 (n136; P0.47). Median change
(interquartile range) in LV end-systolic volume index was0.5 (9.3 to 5.0) versus 1.0 (5.7 to 7.3) mL/m2 (P0.10),
whereas median change (interquartile range) in LV end-diastolic volume index was 3.2 (8.2 to 13.3) versus 5.3 (4.6
to 23.2) mL/m2 (P0.07) in the PCI (n86) and medical therapy–only (n76) groups, respectively.
Conclusions—PCI with stenting of a persistently occluded IRA in the subacute phase after MI effectively maintains
long-term patency but has no effect on LV ejection fraction. On the basis of these findings and the lack of clinical benefit
in the main Occluded Artery Trial, routine PCI is not recommended for stable patients with a persistently occluded IRA
after MI. (Circulation. 2006;114:2449-2457.)
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Late reperfusion has long been thought to be potentiallybeneficial for the many patients who present beyond the
time window proven effective for reperfusion therapy for
acute coronary occlusion.1 Experimental studies have sug-
gested that late reperfusion may reduce adverse left ventric-
ular (LV) remodeling, with resultant better indices of LV size
and function, independent of myocardial salvage,2 through
improved healing or recovery of function of hibernating
myocardium. Because LV size, function, and survival are
closely linked, this effect could underpin improvements in
clinical outcome. Randomized studies examining this hypoth-
esis have been inconclusive.3–7 Post hoc analyses suggesting
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marked improvement in LV function if infarct-related artery
(IRA) patency is maintained6 do not prove an effect of late
reperfusion; both patency and function may be preserved
because of less microvascular dysfunction or more viable
myocardium. Thus, whether to revascularize occluded coro-
nary arteries in the subacute phase of myocardial infarction
(MI) continues to be debated.
Clinical Perspective p 2457
The Occluded Artery Trial (OAT) was an international
randomized trial funded by the National Institutes of Health
that tested the hypothesis that a strategy of percutaneous
coronary intervention (PCI)–based reperfusion would reduce
adverse clinical events over 3 years in stable high-risk
patients with an occluded IRA identified 3 to 28 days after
MI.8 The Total Occlusion Study of Canada (TOSCA)–2 trial,
also funded by the National Institutes of Health, is a mech-
anistic ancillary study of OAT, with 2 primary specific aims:
(1) to determine whether PCI with stenting in addition to
optimal medical therapy in the subacute phase after MI
compared with optimal medical therapy alone yields superior
long-term IRA patency, and (2) to determine whether this
strategy improves LV function and size at 1 year.
Methods
Study Design
TOSCA-2 enrolled participants between May 2000 and July 2005 in
33 of 217 OAT sites with ethics board approval separate from OAT.
(See the Appendix for a listing of participating centers.) TOSCA-2
patients were OAT participants who provided additional informed
consent. Randomization to PCI plus optimal medical therapy (PCI)
or to optimal medical therapy alone (MED) was by a voice-response
system at the Data Coordinating Center that used a randomization
sequence that was separate from OAT and stratified by site.
Patient Sample
Eligibility criteria for TOSCA-2 mirror those for OAT.8 Patients had
a documented MI and underwent cardiac catheterization within 3 to
28 days, with day 1 being the date of symptom onset. Angiographic
criteria included IRA occlusion judged suitable for stenting and at
least 1 high-risk criterion: proximal coronary occlusion subtending at
least 25% of the LV (Figure 1) or LV ejection fraction (LVEF)
50%. IRA occlusion was defined as 100% stenosis with Throm-
bolysis In Myocardial Infarction (TIMI) grade 0 or 1 antegrade
flow.9 All patients were required to (1) have a baseline LV
angiogram suitable for quantitative analysis and (2) agree to
follow-up cardiac catheterization. Patients with clinical instability,
left main or 3-vessel disease, or severe inducible ischemia were
excluded. Retrospective enrollment of OAT participants (which was
allowed provided that in a given TOSCA-2–approved site, consec-
utive patients were enrolled to minimize selection bias) occurred in
37 cases.
Study Procedures
Patients assigned to PCI were to undergo the procedure within 24
hours of randomization; whenever possible, 1 or more locally
approved coronary stents were to be deployed, and a glycoprotein
IIb/IIIa inhibitor was to be used. Drug-eluting stents were deployed
in 29 cases. Thienopyridine therapy was recommended to commence
before PCI and to continue for 2 to 4 weeks after PCI and to be used
for 1 year in both groups after publication of the efficacy of
longer-duration clopidogrel therapy.10 Angiographic follow-up was
obtained 123 months after randomization.
Angiographic Analysis
Sites were certified after core laboratory review of angiograms of
PCI of total coronary occlusions and procedural statistics of pro-
posed TOSCA-2 operators.8 Guidelines for angiographic images
included reproduction of baseline views, extended cine runs for
antegrade and collateral flow assessment, and use of intracoronary
nitroglycerin. Whenever possible, a standardized calibration ball was
used to allow calculation of LV volume end points.
Angiographic images were analyzed at a core laboratory with the
ImageComm system (Quinton, Bothell, Wash). Coronary luminal
diameter, including 5-mm-long perilesional segments, was measured
to obtain in-stent and in-lesion minimal luminal diameter. Restenosis
was defined as 50% diameter stenosis at the point of in-lesion
minimal luminal diameter with proximal-only reference segments.
Antegrade and collateral flow was scored with standard criteria,9,11
with late patency defined as antegrade flow grades 2 or 3 irrespective
of lumen dimensions. The area-length method was used to measure
LVEF and LV volumes when calibration images were provided.
Regional wall motion was measured by the centerline method.12
Study End Points
Two coprimary end points were specified: (1) follow-up IRA
patency and (2) change in LVEF. Secondary end points included
change in LV end-systolic volume index (LVESVI), LV end-diastol-
ic volume index (LVEDVI), and regional wall-motion score. With
Data Safety Monitoring Board approval, the Steering Committee
changed the original protocol-defined coprimary end point of
LVESVI to LVEF after 1 year of enrollment,13 to avoid systematic
exclusion of patients with study-qualifying angiograms performed at
non-OAT sites without routine calibration. LVESVI and LVEDVI
were retained as secondary end points. Clinical events were adjudi-
cated by an independent Mortality and Morbidity Classification
Committee blinded to treatment assignment.8
Statistical Analysis
An intention-to-treat principle was used for all treatment-related
analyses unless otherwise specified. Patency was evaluated with
0.01 for a 2 test of proportions and LVEF with 0.04 for a
2-sided, 2-group t test comparing change in LVEF from baseline to
1 year between the 2 treatment groups. As in the main OAT trial, a
probability value of 0.01 for secondary analyses was considered
strong evidence of association. The planned study size was 380
patients (190 patients per group), which would provide 90% power
to detect a difference in the absolute change in LVEF between the
study groups of 4%, based on observations of LVEF change and SD
of change among similar subjects enrolled in prior studies6,14
(common SD of 8.0%) and the following assumptions: 25% cross-
Figure 1. IRA segment study eligibility
criteria with LVEF 50% for (A) a left-
dominant system, (B) a right-dominant
system, and (C) right coronary artery in a
right-dominant system. Eligibility when
LVEF was 50% required that the
occluded artery supply at least 25% of
the LV.
2450 Circulation December 5, 2006
 by guest on December 20, 2012http://circ.ahajournals.org/Downloaded from 
overs (PCI in MED patients and no attempt at PCI or failed PCI,
which are biological crossovers, in the PCI-assigned patients) and
15% loss of ventriculogram data. A total of 381 patients were
enrolled; 332 (87%) had paired angiographic data, and 286 (75%)
had paired ventriculographic data (for LVEF assessment), of which
162 (42%) were calibrated (for LVESVI and LVEDVI measure-
ment). The observed percent crossovers were 14 (8% with unsuc-
cessful PCI in the PCI group and 6% with PCI in the MED group).
With an observed SD of 8.6% for LVEF change, TOSCA-2 had 94%
power to detect a difference of 4.0% and 81% power to detect a
difference of 3.25% in the change in LVEF between the 2 study
groups. The study also had 78% power to detect a difference in
change in mean LVESVI of 12 mL/m2 assuming the observed SD of
20.8. For patency, TOSCA-2 had 85% power to detect an absolute
difference of 25% in patency between the 2 treatment groups.
Change in LVEF was normally distributed and suitable for the
2-group t test. Changes in LVESVI and in LVEDVI were not
normally distributed and were analyzed with the nonparametric
Wilcoxon rank-sum test.
For multivariable models, we used stepwise linear regression for
continuous outcomes and logistic models for binary outcomes. The
prespecified variables tested in each stepwise model were as follows:
PCI group, age, sex, race, days from MI to randomization, prior MI,
hypertension, diabetes mellitus, multivessel disease, collateral arter-
ies, ST-segment elevation MI (STEMI) on ECG (ST elevation and/or
new Q waves and/or loss of R waves), left anterior descending
coronary artery culprit, -blockers, angiotensin-converting enzyme
inhibitor or angiotensin receptor blocker, thrombolysis, and baseline
LVEF, plus baseline LVESVI for the LVESVI model and baseline
LVEDVI for the LVEDVI model. Because models of change in
LVESVI and LVEDVI had normally distributed residuals that
exhibited homoscedasticity, these measures were suitable for analy-
sis with linear regression. We also performed a sensitivity analysis
using these variables in a multiple imputation procedure for missing
LVEF data.
The authors had full access to the data and take full responsibility
for the integrity of the data. All authors have read and agree to the
manuscript as written.
Results
A total of 381 patients were enrolled, representing 67% of all
contemporaneous OAT enrollments at TOSCA-2 centers
(18% of the 2166 OAT patients). Follow-up angiography was
performed in 332 patients (87%) at a median 379 days
(interquartile range, 363 to 417 days) after randomization
(Figure 2).
Baseline Characteristics
The PCI and MED groups were similar in most respects
(clinical [Tables 1 and 2] and angiographic [Table 3]) and
were similar to other OAT patients with the exception of
Killip class II during the index MI (12.3% versus 20.7%).
A STEMI ECG was found in 86%. Fewer than one fourth of
all patients had received fibrinolytic therapy. Median interval
from MI to randomization was 10 days. The 49 patients who
did not undergo follow-up angiography were more likely to
be diabetic, to have a lower baseline LVEF, and to have a
higher index MI Killip class than those with follow-up
angiograms. Characteristics of these patients were similar
across treatment groups.
Postrandomization Medical Therapy
The utilization of proven medical therapies was high and
similar in the 2 groups with the exception of thienopyridines,
taken by all patients with successful PCI but by fewer than
one third of MED patients (Table 4).
Revascularization: PCI Group
All PCI-assigned patients underwent target-vessel interven-
tion, 76% within 24 hours and 96% within 32 hours of
randomization. Glycoprotein IIb/IIIa inhibitors were used in
81%. Core laboratory–adjudicated procedural success was
present in 91.8%, and stents were deployed in all but 1
successful case. TIMI grade 3 flow was achieved in 85.1%
and grade 2 in 5.6% (Table 5). Four patients (2.1%) with
50% residual epicardial stenosis but post-PCI TIMI grade 1
flow presumed due to microvascular obstruction were adju-
dicated as PCI successes. Among successful procedures,
immediate postprocedural diameter stenosis was 4.6% in-
stent and 28.7% in-lesion. There were few procedural com-
plications (6 complications, 5 PCI-related: 1 cardiogenic
shock, 1 coronary dissection, 1 limb ischemia, and 2 Mortal-
ity and Morbidity Classification Committee–adjudicated
MIs). In addition, within 48 hours of study entry, site-
reported reelevation of serum myocardial biomarkers was
present in 17 (9.2%) of 184 of the PCI group and 7 (4.5%) of
154 of the MED group (P0.09). Four patients (2.1%)
underwent non-IRA intervention at the time of index PCI. By
1 year, performance of nonprotocol (including non-IRA) PCI
occurred in 9 PCI-assigned patients (4.6%), repeat PCI of the
IRA in 4 (2.1%), and coronary artery bypass grafting in 4
(2.1%) patients.
Revascularization: MED Group
Fourteen MED-assigned patients (7.5%) underwent PCI of
the IRA within 1 year of randomization. Reasons for cross-
over included unstable angina, a positive stress test, ventric-
ular arrhythmia, silent ischemia, and physician preference.
During this period, PCI of non-IRA vessels was performed in
Figure 2. TOSCA-2 study flow.
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10 patients (5.4%) and coronary artery bypass grafting in 2
(1.1%).
Primary End Point
Late patency was observed in 143(83%) of 173 PCI and 40
(25%) of 159 MED patients (P0.0001; Table 5). TIMI 3
flow was present in 130 PCI patients (75%) and 20 MED
patients (13%; P0.0001). Among those with initially suc-
cessful interventions, late patency was observed in 89% and
TIMI 3 flow in 82%.
Analyzable, paired LV angiograms were available in 150
PCI patients (77%) and 136 MED patients (73%), with
another 23 PCI and 23 MED angiograms being technically
inadequate and 22 PCI and 27 MED not performed. LVEF
improved significantly in both groups, but there was no
between-groups difference: mean change in LVEF was
4.28.9% in the PCI group and 3.58.2% in the MED group
(P0.47; Figure 3; Table 6). As-treated and imputed second-
ary analyses of LVEF change by treatment yielded similar
results. On multivariable analyses of change in LVEF, left
anterior descending coronary artery culprit (P0.02) was a
positive predictor, and age (P0.03) was a negative predic-
tor. Presence of a STEMI ECG (P0.07) was a weak positive
predictor. There was no effect of PCI (P0.38) or time from
MI to randomization. Regardless of initial treatment assign-
ment, patients with a patent IRA at follow-up had a greater
increase in LVEF than those with an occluded artery (abso-
lute difference of 3.0%; P0.003).
Secondary End Points
Univariate analyses demonstrated a trend favoring PCI in
attenuating absolute and percentile diastolic and systolic
volume increases (LVEDVI: absolute change P0.07, per-
cent change P0.09; LVESVI: absolute change P0.10,
percent change P0.07; Figure 3; Table 6). Multivariable
analyses showed assignment to PCI to be an independent
predictor of smaller absolute increase (P0.02) and percent
change (P0.04) in LVEDVI. Other independent predictors
of smaller LVEDVI increase were baseline LVEF
(P0.002), baseline LVEDVI (P0.001), and left anterior
descending coronary artery culprit (P0.04). There was no
association with time from MI to randomization. PCI also
independently predicted a smaller percent increase in
LVESVI (P0.04). Baseline LVEF (P0.004), LVESVI
(P0.005), and a left anterior descending coronary artery
culprit (P0.02) were other independent predictors of a
smaller percent increase in LVESVI. There was a weak trend
toward STEMI ECG predicting a greater percent increase
TABLE 1. Baseline Clinical Characteristics
Variable PCI (n195) MED (n186)
Mean age (range), y 57.3 (34–80) 57.8 (33–81)
Female, n (%) 33 (16.9) 33 (17.7)
Race, n (%)
White 160 (82.1) 151 (81.2)
Black 6 (3.1) 5 (2.7)
Other 29 (14.9) 30 (16.1)
No. (%) with history of:
Diabetes* 32 (16.4) 47 (25.3)
Hypertension 89 (45.6) 92 (49.5)
Hyperlipidemia 108 (55.4) 111 (59.7)
Prior MI 25 (12.8) 17 (9.1)
Cerebrovascular disease† 11 (5.6) 1 (0.5)
PVD 5 (2.6) 3 (1.6)
CHF 4 (2.1) 3 (1.6)
Prior PCI 8 (4.1) 4 (2.2)
Current smoker, n (%) 66 (33.8) 65 (34.9)
NYHA class at randomization, n (%)
Class I 182 (93.3) 170 (91.4)
Class II 13 (6.7) 16 (8.6)
Class III or IV 0 0
Body mass index,† meanSD 27.54.2 (n195) 28.85.1 (n186)
Heart rate, bpm, meanSD 69.212.2 (n195) 69.812.4 (n186)
Systolic blood pressure, mm Hg, meanSD 116.616.0 (n195) 117.117.0 (n186)
Diastolic blood pressure, mm Hg, meanSD 71.011.2 (n195) 70.812.1 (n186)
Serum creatinine, mg/dL, meanSD 1.00.2 (n191) 1.00.2 (n184)
Creatinine clearance, mL/min, meanSD 83.119.8 (n191) 82.321.4 (n184)
PVD indicates peripheral vascular disease; CHF, congestive heart failure.
*P0.03, †P0.01.
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(P0.09). No interaction was observed between the effect of
PCI and STEMI ECG, large infarct size by serum marker
elevation, below-median LVEF (49%), or left anterior de-
scending coronary artery culprit on change in LV volumes.
Regardless of treatment assignment, patients with an oc-
cluded IRA at follow-up had more LV dilation than those
with a patent artery (absolute change in LVESVI P0.003,
and absolute change in LVEDVI P0.03).
Both groups demonstrated significant improvement in
target-region wall-motion score; the change over 1 year
tended to be greater in the PCI group. The angiographic
restenosis rate in the PCI group was 45.7% (Table 5).
The 12-month cumulative event rate for the Mortality and
Morbidity Classification Committee–adjudicated primary
OAT end point of death, MI or New York Heart Association
class IV congestive heart failure was 6.2% in the PCI group
and 6.5% in the MED group. The adjudicated MI cumulative
event rate was 2.6% and 3.8% in these 2 groups. The study
was not powered to detect differences in event rates.
Discussion
A strategy of stent-based PCI for persistently occluded IRA
diagnosed in the subacute post-MI period resulted in IRA
patency in four fifths of patients at 1 year, triple the rate
observed in medically treated patients. This did not result in
significant improvement in LVEF. In the 42% subset with
volumetric measures, PCI appeared to be independently
predictive of somewhat less LV dilation over 1 year.
Small randomized studies examining this issue in the
balloon angioplasty era were negative or inconclusive.4,6,7 In
spite of the efficacy of stenting of coronary occlusions,15,16
studies using routine stenting and showing excellent long-
term patency have continued to show mixed or inconclusive
results.3,5
The postulated mechanisms underpinning the potential
benefits of late opening of the IRA center on improvement of
LV function and reduction of LV remodeling. The present
study had excellent statistical power to address the former but
less so for the latter, and only in a subgroup of patients. The
TOSCA-2 results show that late PCI of an occluded IRA does
not improve LVEF at 1 year compared with medical therapy
alone. Significant improvement in LVEF was observed in
both groups.
LV dilation begins early in the course of acute MI as a
result of necrosis and myofibril slippage and is associated
TABLE 2. Index MI Characteristics
Variable
PCI
(n195)
MED
(n186)
Confirmatory evidence of index MI
Chest pain or equivalent 189 (96.9) 185 (99.5)
Any positive serum marker 187 (95.9) 177 (95.2)
ST-T changes, new LBBB 159 (81.5) 158 (84.9)
ST-elevation or new Q-waves or
loss of R-waves
163 (83.6) 165 (88.7)
High serum marker,* n/N (%) 101/187 (54.0) 88/177 (49.7)
Therapy during first 24 hours of MI
Thrombolytic agent only 46 (23.6) 39 (21.0)
GP IIb/IIIa inhibitor 7 (3.6) 10 (5.4)
Combination 4 (2.1) 1 (0.5)
None of the above 136 (69.7) 134 (72.0)
Unknown 2 (1.0) 2 (1.1)
Interval from MI to randomization
7 d 64 (32.8) 70 (37.6)
8–14 d 62 (31.8) 53 (28.5)
15–28 d 67 (34.4) 62 (33.3)
29 d 2 (1.0) 1 (0.5)
Median, d 10.0 10.0
LBBB indicates left bundle-branch block; GP, glycoprotein. Values are n (%),
unless otherwise indicated.
*Above-median value of the ratio of the peak serum marker to the upper
limit of normal.
TABLE 3. Baseline Angiographic Characteristics: Angiographic
Core Laboratory Data
Variable
PCI
(n195)
MED
(n186)
IRA, n (%)
LAD 60 (30.8) 79 (42.5)
Circumflex 28 (14.4) 22 (11.8)
RCA 107 (54.9) 85 (45.7)
IRA TIMI flow grade, n (%)
Grade 0 155 (79.9) 155 (83.3)
Grade I 37 (19.1) 31 (16.7)
Grade II 2 (1.0) 0 (0.0)
Missing 1 0
Collateral grade in IRA, n (%)
Grade 0 21 (10.9) 17 (9.2)
Grade I 138 (71.5) 135 (73.0)
Grade II 34 (17.6) 33 (17.8)
Missing 2 1
No. of diseased vessels
70%, n (%)
Single 159 (81.5) 158 (84.9)
Double 34 (17.4) 28 (15.1)
Triple 2 (1.0) 0 (0.0)
LVEF 50%, n/N (%) 95/183 (51.9) 87/170 (51.2)
Proximal occlusion, n (%) 179 (91.8) 175 (94.1)
LVEF 50% or proximal
occlusion, n/N (%)
192/195 (98.5) 184/186 (98.9)
LVEF 50% and not proximal 3/195 (1.5) 2/186 (1.1)
LV function and volume baseline
values, meanSD
LVEF, % (PCI, MED: n183,
170)
48.210.6 47.510.7
LVESVI, ml/m2 (n105, 97) 34.919.5 33.915.2
LVEDVI, ml/m2 (n105, 97) 67.932.1 64.124.2
Target-region wall motion
(SD/chord) (n182, 170)
2.990.91 3.080.81
LAD indicates left anterior descending coronary artery; RCA, right coronary
artery.
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with microvascular dysfunction.17 Dilation portends a poor
long-term outcome. Prior evidence for an association between
persistent IRA occlusion and late-phase LV remodeling,18
characterized by increased contractile segment length and
change in shape toward the spherical,19 is more robust than
the evidence for the association of IRA status and global LV
systolic function.
The present trial was able to assess the effect of late PCI
of an occluded IRA on LV remodeling only as a secondary
end point and only in a subgroup of patients selected on the
basis of technical features of the LV angiogram and on
patient compliance with the second catheterization. We
found a trend toward a smaller increase in LVEDVI in the
PCI group compared with the MED group; on multivari-
able analysis, including adjustment for baseline imbal-
ances, there was an independent effect of PCI leading to
less LV dilation over 1 year. Whether the strength of the
observed association would be greater or less if the full
cohort were evaluated is unclear.
At least moderately retained viability in the infarct zone
was found at baseline in 69% of 124 patients in an OAT
ancillary study.20 In TOSCA-2, both treatment groups had
significant improvement in target-region wall motion, and
there was a trend toward greater improvement in the PCI
group. The heterogeneity of the response implies that mech-
anisms other than vessel patency are operative.
TABLE 4. Utilization of Medical Therapies at Discharge
Discharge 1 Year
Agent PCI (n195) MED (n186) PCI (n184) MED (n172)
Aspirin 99.0 96.8 94.6 94.2
Thienopyridine (clopidogrel or ticlopidine) 92.8 30.6* 33.1 23.3
Aspirin or thienopyridine 100.0 99.5 96.2 97.7
Aspirin plus thienopyridine 91.8 28.0* 22.3 12.8†
Warfarin 8.7 16.1 NC NC
One or more of ASA, warfarin, thienopyridine 100.0 100.0      
Two or more of ASA, warfarin, thienopyridine 93.3 41.9*      
-Blocker 88.7 94.1 85.3 93.6†
ACE inhibitor or ARB 86.7 89.8 87.5 90.1
Spironolactone 4.1 7.5 9.2 11.0
Lipid-lowering agent 83.6 85.5 88.6 90.7
ASA indicates aspirin; NC, not collected; ACE, angiotensin-converting enzyme; and ARB, angiotensin receptor
blocker. All values are percentages.
*P0.001 at discharge; †P0.05 at 1 year.
TABLE 5. IRA PCI Procedural and 1-Year Results
PCI MED
Variable
Baseline
(n195)
Post-PCI
(n195)
1 Year
(n173)
Baseline
(n186)
1 Year
(n159)
TIMI grade flow†
Grade 0 155 (79.9) 12 (6.2) 22 (12.7) 155 (83.3) 57 (35.8)
Grade 1 37 (19.1) 6 (3.1) 8 (4.6) 31 (16.7) 62 (39.0)
Grade 2 2 (1.0) 11 (5.6) 13 (7.5) 0 (0.0) 20 (12.6)
Grade 3 0 (0.0) 166 (85.1) 130 (75.1) 0 (0.0) 20 (12.6)
TIMI grade 2 or 3† 2 (1.0) 177 (90.8) 143 (82.7) 0 40 (25.2)
Missing 1 0 22 0 27
In-lesion
MLD, mm* 0.0020.02 2.10.8 1.50.9 0 0.30.6
% Diameter stenosis* 99.82.6 34.323.6 52.526.6 1000.4 90.217.4
Late loss index       0.270.36      
In-stent
MLD, mm    2.70.6 1.70.9      
% Diameter stenosis    15.916.4 45.926.8      
Restenosis rate %       45.7      
MLD indicates minimal luminal diameter.
*P0.001, †P0.0001 for 1-year PCI vs MED comparison.
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The results of TOSCA-2 must be interpreted in the
context of OAT. TOSCA-2 confirms that PCI resulted in
1-year patency exceeding 80%, yet OAT showed that PCI
did not reduce the combined end point of death, recurrent
MI, or New York Heart Association class IV congestive
heart failure.20 Prior studies of pharmacotherapy suggest
that attenuation of LV remodeling to the degree observed
in the present study, if it were generalizable to all OAT
patients, should have had clinical importance.21 OAT and
TOSCA-2 patients received angiotensin-converting en-
zyme inhibitors and -blockers, agents known to attenuate
the maladaptive neurohumoral response that contributes to
late-phase LV remodeling.22 This background therapy may
have diminished the therapeutic potential of late revascu-
larization. We confirmed that patients with low LVEF
were at greatest risk for LV dilation. The absolute effect of
PCI was greatest in those patients; however, the same
relative effect was seen across the range of LVEFs. Indeed,
in OAT, there was no interaction between the effect of PCI
and LVEF on clinical outcomes.20
Interestingly, the modest potential PCI-related benefit in
ventricular volumes suggested in TOSCA-2, coupled with the
trend toward excess reinfarction observed in OAT, is consis-
tent with PCI as a therapy that presents competing effects. LV
remodeling may be attenuated, but the same procedure is
associated with excess risk of reinfarction, seen in the overall
OAT cohort. Extended clinical follow-up of the OAT cohort
to better define the balance between a potential long-term
benefit resulting from improved LV remodeling versus the
adverse effect of the trend toward excess reinfarction20 is
being planned.
Study Limitations
Although the angiographic follow-up rate up was at least
comparable to that in other angiographic studies, TOSCA-2
was limited by a small proportion of technically inadequate
LV angiograms and lack of calibration in almost half of the
analyzable paired LV angiograms, which decreased power for
the volume end points. Follow-up angiography reflects bias,
with sicker patients not returning. It is unknown whether the
apparent beneficial effect of PCI on LV remodeling observed
in a subset extends to the entire cohort.
Conclusions
A strategy of PCI to recanalize persistently occluded IRAs in
stable patients 3 to 28 days after MI is effective in establish-
ing and maintaining long-term patency of the IRA but does
not improve LVEF. Progressive LV dilation over 1 year
appears to be modestly attenuated in the subset with available
data. On the basis of these findings and the lack of clinical
benefit over an average 3-year follow-up in OAT, routine PCI
is not recommended for persistent IRA occlusion in stable
patients days to weeks after MI.
Appendix
Executive Committee: V. Dzˇavík (Principal Investigator),
C.E. Buller (Coprincipal Investigator), J.S. Hochman, G.A.
Lamas, and G.L. Knatterud. Global TOSCA-2 Coordinator:
D. Atchison. Steering Committee: Executive Committee
members and G.B. Mancini, W. Cantor, E.A. Cohen, R.G.
Carere, T.J. Anderson, A. Glanz, D. Almond, W.J. Rankin, J.
Renkin, and J. Col. Angiographic Core Laboratory: CIRCL,
University of British Columbia (G.B. Mancini, C.E. Buller,
and E. Yeoh). Data Coordinating Center: Maryland Medical
Research Institute (G.L. Knatterud, S. Forman, and B. Bar-
ton). Participating Centers (number of patients enrolled):
Argentina: Hemodinamia Rosario—C.R. Vozzi, M. Car-
donna (14). Australia: Royal Perth Hospital—J.M. Rankin,
A.M. Tunesi (15). Belgium: Cliniques Universitaires UCL St.
Luc—J.P.M. Renkin, J. Col, R. Lauwers (4). Brazil: Hospital
Socor—J.A. Saad, M.C. Machado (11); Hospital Sao Lu-
cas—P.R.A. Caramori, R. Lasevitch, P. Hickmann (3). Can-
ada: Vancouver General Hospital—C.E. Buller, R.S. Fox
(49); Toronto General Hospital—J.R. Ross, A.R. Patel (41);
St. Michael’s Hospital—W.J. Cantor, B. Strauss, A. Fry, A.
Figure 3. Comparison of (A) baseline and follow-up LVEF (pri-
mary LV function end point; between group P0.47), (B)
LVESVI, and (C) LVEDVI in the 2 study groups. Box-and-
whiskers plots indicate medians, means, and interquartile
ranges. Probability values indicate baseline to 1-year compar-
isons within each group and between groups as indicated.
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DiMarco (32); St. Paul’s Hospital—R.G. Carere, J.G. Webb,
T. Kot, L. Milosavljevi (23); Hotel Dieu Grace Hospital—A.
Glanz, R. Chetty, C. Vilag (16); Sunnybrook Hospital—E.A.
Cohen, L. Balleza (16); University of Alberta Hospital—J.R.
Burton, N. Hogg, L. Lindholm (11); Royal Alexandra Hos-
pital—N. Brass, C. Buck (9); London Health Sciences Cen-
tre, Victoria Campus, London—D. Almond, P. Teefy, D.
Wiseman (9); Queen Elizabeth II H.S.C—L.M. Title, N.
Fitzgerald (8); L’Institut de Cardiologie de Montreal—L.
Bilodeau, N. St. Jean, N. Hardy (7); Peterborough Regional
Health Centre—A. Abdullah, A. Janmohammed, B. Potvin
(7); The Scarborough Hospital—J. Cherry, J. Smith (4);
University of Ottawa Heart Institute—M. Labinaz, N. Shore,
E. Brilliant (4); Foothills Hospital—T.J. Anderson, L. Mann
(3); Hospital Maisonneuve-Rosemont—C. Constance, M.-F.
Gauthier (2); Trillium Health Centre—C. Lazzam, A. Carter
(2); London Health Sciences Centre—W.J. Kostuk, S. Carr
(2); St. Boniface General Hospital—A. Miller, M.-L. Wilson
(1); CHUM, Notre Dame—F. Reeves, M.-C. Pashko (1);
Hospital Sacre Coeur—E. Schampaert, D. Palisaitis, C. Mer-
cure, M.A. Capobianco (1). New Zealand: Waikato Hospi-
tal—G. Devlin, D. Peek, L. Low (15). Poland: Upper Silezian
Cardiac Center—P. Buszman, A. Zurakowski (19); T. Mar-
ciniak Hospital—K. Loboz-Grudzien, L. Sokalski (12). Por-
tugal: Hospital Fernando Fonseca—P.F. Abreu, B. Thomas,
M. Nedo (18). Slovakia: Central Slovak Institute of Cardio-
vascular Diseases—P. Meiar, P. Kurray (15); Slovak Institute
of Cardiovascular Diseases—V. Fridrich, S. Mizera (5).
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CLINICAL PERSPECTIVE
Nearly a third of patients diagnosed with ST-elevation myocardial infarction receive no reperfusion therapy for acute
coronary occlusion, many because of late presentation. Half of these patients will have persistent occlusion of the
infarct-related artery. The Total Occlusion Study of Canada (TOSCA)--2, an angiographic substudy of the 2166-patient
Occluded Artery Trial (OAT), randomized 381 stable patients with persistent infarct-related artery occlusions days to
weeks after MI to percutaneous coronary intervention (PCI) or medical therapy alone, to determine if PCI would improve
left ventricular (LV) function and attenuate post MI adverse (LV) remodeling. Despite excellent patency 1 year after PCI,
no salutary effect on LV ejection fraction was observed. PCI appeared, however, to be independently predictive of a modest
reduction in adverse remodeling in a subgroup of patients with LV volume measurement, an observation that may or may
not apply to the full cohort. This benefit did not translate into an effect on clinical events either in TOSCA-2 (not powered
for clinical events), or in the well-powered OAT study, which conversely suggested excess reinfarction in PCI-assigned
patients. These discordant observations imply competing effects of PCI in this setting: a potential modest beneficial effect
on LV remodeling counterbalanced by excess reinfarction over an average 3-year follow-up in OAT. Thus, there is no
indication for PCI of persistently occluded IRAs in stable patients in the days to weeks after MI. Whether the clinical
balance between a potential remodeling benefit and an adverse effect of excess reinfarction will sway toward a significant
difference in favor of either medical therapy alone or PCI over the long-term is unknown.
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